{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-21-000025","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.418776+00:00","generated_at":"2026-06-28T10:12:23.241830+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Maravai Q3 revenue up 133% to $204.8M; raises 2021 guidance, provides 2022 outlook","bullets":["Q3 revenue $204.8M (+133% YoY); net income $132.8M (+240%); Adj EBITDA $156.0M.","Nucleic Acid Production revenue $182.9M (+170% YoY) on demand for CleanCap mRNA vaccine components.","2021 guidance raised: revenue $770-780M, Adj EBITDA $570-575M, Adj diluted EPS $1.48-$1.52.","Initial 2022 revenue guidance $840-880M, representing ~11-14% growth at midpoint after adjusting for divestiture.","Completed sale of Protein Detection business; published inaugural ESG report."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-21-000025","json":"https://secwatch.observer/filing/0001823239-21-000025.json","markdown":"https://secwatch.observer/filing/0001823239-21-000025.md","text":"https://secwatch.observer/filing/0001823239-21-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323921000025/0001823239-21-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323921000025/mrvi-20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:12:23.241830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}